DNA-Antibody Hybrid Molecule Shown to Be Effective Antibacterial Agent
|
By LabMedica International staff writers Posted on 18 May 2015 |

Image: Alphamers (purple) act as homing beacons, attracting pre-existing anti-alpha-Gal antibodies (green) to the bacterial surface (Photo courtesy of Altermune Technologies).

Image: Dr. Kary Mullis, founder of Altermune Technologies, received the Nobel Prize for chemistry in 1993 for his invention of the polymerase chain reaction (PCR) )Photo courtesy of Altermune Technologies).
A hybrid molecule comprising an aptamer attached to a trisaccharide terminating with alpha-gal (N-acetyl-glucosamine) was shown in a proof-of-principle study to be an effective antibacterial agent.
Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies, as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. Relative to monoclonal antibodies, aptamers are small, stable, and non-immunogenic.
Humans do not express the galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-Gal) epitope. However, as a result of exposure to alpha-Gal in the environment, humans develop a large quantity of circulating antibodies that are specific for this trisaccharide.
Investigators at the University of California, San Diego (USA) developed a DNA aptamer that was able to bind to group A Streptococcus (GAS) bacteria by recognition of a conserved region of the surface-anchored M protein. To the 5′ end of this aptamer they conjugated an alpha-Gal epitope. This hybrid molecule was termed an "alphamer." The intent was that the aptamer segment of the alphamer would attach the molecule to the target bacterium while the alpha-Gal fragment would bind to the body's normally circulating anti-alpha-Gal antibodies.
In a paper published in the May 5, 2015, online edition of the Journal of Molecular Medicine the investigators showed that an anti-GAS alphamer could recruit anti-Gal antibodies to the streptococcal surface in an alpha-Gal-specific manner, elicit uptake and killing of the bacteria by human phagocytes, and slow growth of invasive GAS organisms in human whole blood.
These results constituted the first in vitro proof of concept that alphamers had the potential to redirect preexisting antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response.
"We are picturing a future in which doctors have a case full of pathogen-specific alphamers at their disposal," said senior author Dr. Victor Nizet, professor of pediatrics and pharmacy at the University of California, San Diego. "They see an infected patient, identify the causative bacteria, and pull out the appropriate alphamer to instantly enlist the support of the immune system in curing the infection."
The alphamer concept was attributed to contributing author Dr. Kary Mullis, winner of the 1993 Nobel Prize for chemistry for his invention of the polymerase chain reaction (PCR), technique. Dr. Mullis has established a biotech company, Altermune Technologies (Irvine, CA, USA), to develop alphamers into commercially viable therapeutic tools.
Related Links:
University of California, San Diego
Altermune Technologies
Aptamers are nucleic acid species that have been engineered through repeated rounds of in vitro selection to bind to various molecular targets such as small molecules, proteins, and nucleic acids. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of antibodies. In addition to their discriminate recognition, aptamers offer advantages over antibodies, as they can be engineered completely in a test tube, are readily produced by chemical synthesis, possess desirable storage properties, and elicit little or no immunogenicity in therapeutic applications. Relative to monoclonal antibodies, aptamers are small, stable, and non-immunogenic.
Humans do not express the galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-Gal) epitope. However, as a result of exposure to alpha-Gal in the environment, humans develop a large quantity of circulating antibodies that are specific for this trisaccharide.
Investigators at the University of California, San Diego (USA) developed a DNA aptamer that was able to bind to group A Streptococcus (GAS) bacteria by recognition of a conserved region of the surface-anchored M protein. To the 5′ end of this aptamer they conjugated an alpha-Gal epitope. This hybrid molecule was termed an "alphamer." The intent was that the aptamer segment of the alphamer would attach the molecule to the target bacterium while the alpha-Gal fragment would bind to the body's normally circulating anti-alpha-Gal antibodies.
In a paper published in the May 5, 2015, online edition of the Journal of Molecular Medicine the investigators showed that an anti-GAS alphamer could recruit anti-Gal antibodies to the streptococcal surface in an alpha-Gal-specific manner, elicit uptake and killing of the bacteria by human phagocytes, and slow growth of invasive GAS organisms in human whole blood.
These results constituted the first in vitro proof of concept that alphamers had the potential to redirect preexisting antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response.
"We are picturing a future in which doctors have a case full of pathogen-specific alphamers at their disposal," said senior author Dr. Victor Nizet, professor of pediatrics and pharmacy at the University of California, San Diego. "They see an infected patient, identify the causative bacteria, and pull out the appropriate alphamer to instantly enlist the support of the immune system in curing the infection."
The alphamer concept was attributed to contributing author Dr. Kary Mullis, winner of the 1993 Nobel Prize for chemistry for his invention of the polymerase chain reaction (PCR), technique. Dr. Mullis has established a biotech company, Altermune Technologies (Irvine, CA, USA), to develop alphamers into commercially viable therapeutic tools.
Related Links:
University of California, San Diego
Altermune Technologies
Latest BioResearch News
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







